Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive cognitive decline. Its pathological mechanisms are complex, involving multiple key links such as beta-amyloid protein (Aβ) deposition, excessive phosphorylation of Tau protein, neuroinflammation and synaptic dysfunction. Traditional Chinese medicine (TCM) categorizes AD under conditions like “dementia” and “forgetfulness”, with the core pathogenesis being “deficiency at the root and excess at the surface”, where kidney essence deficiency is the root cause and phlegm turbidity and blood stasis obscuring the orifices are the surface manifestations. As a distinctive TCM therapy, aromatic orifice-opening drugs, with their pungent, fragrant and penetrating nature that can reach and regulate meridians, follow the principle of “awakening the orifices and refreshing the mind, resolving phlegm and dispelling foulness”, demonstrating unique advantages in the prevention and treatment of AD. Representative drugs include Shichɑngpu (Acori Tatarinowii Rhizoma), Yuanzhi (Polygalae Radix), Shexiang (Moschus), Bingpiɑn (Borneolum Syntheticum), etc. Modern pharmacological research has revealed their multi-target intervention potential, including inhibiting Aβ generation and aggregation, reducing Tau protein phosphorylation, anti-neuroinflammation, anti-oxidative stress, and regulating neurotransmitters and promoting neurogenesis. Commonly used TCM formulas with the effect of aromatic orifice-opening such as Angong Niuhuang Pill (安宫牛黄丸), Suhexiang Pill (苏合香丸) and Changpu Yujin Decoction (菖蒲郁金汤) have shown good efficacy in improving patients’ cognitive function, memory, and daily living abilities through compatibility and synergy. This review systematically summarizes the research and application status of aromatic orifice-opening drugs in the prevention and treatment of AD, providing theoretical basis and practical references for the intervention of AD by aromatic orifice-opening TCMs.
Key words
Alzheimer’s disease
/
aromatic orifice-opening drugs
/
compatibility of traditional Chinese medicine
/
Acori Tatarinowii Rhizoma
/
Polygalae Radix
/
Moschus
/
Borneolum Syntheticum
HE Haili, LI Yuan, WANG Hongyan, ZHANG Can, YUAN Xianjiang, YANG Hongwei, CHEN Shaoxu, QIAN Haibing.
Pharmacological research and application of aromatic orifice-opening drugs in prevention and treatment of Alzheimer’s disease[J].
Chinese Traditional and Herbal Drugs,
2026
, 57
(15)
: 6172
-6182
.
DOI: 10.7501/j.issn.0253-2670.2026.15.032
基金
收起
贵州省高等学校中药 (民族药); 贵州省科技计划项目 (黔科合基础-ZK [2022]一般471)
参考文献
收起
文献
收起
参考文献引证文献
排序方式：
Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer’s disease [J]. Lancet, 2021, 397(10284): 1577-1590. Chen Y G. Research progress in the pathogenesis of Alzheimer’s disease [J]. Chin Med J, 2018, 131(13): 1618-1624. Jia J P, Ning Y Y, Chen M L, et al. Biomarker changes during 20 years preceding Alzheimer’s disease [J]. N Engl J Med, 2024, 390(8): 712-722. Pei H, Ma L N, Cao Y, et al. Traditional Chinese medicine for Alzheimer’s disease and other cognitive impairment: A review [J]. Am J Chin Med, 2020, 48(3): 487-511. 逄冰, 刘文科, 周强, 等. 芳香药物效用探析[J]. 中医杂志, 2013, 54(18): 1616-1618. 王利苹, 奉建芳, 胡凯莉. 芳香开窍中药对血脑屏障通透性的调节作用及其机制研究进展[J]. 中国中药杂志, 2014, 39(6): 949-954. 何英, 张蓓, 周志聪. 阿尔茨海默症的中草药康复景观研究进展[J]. 医药前沿, 2025, 15(17): 29-32. 史鸣飞, 杨燕, 李子贇, 等. 从玄府论治老年期痴呆探讨[J]. 世界中医药, 2022, 17(5): 727-730. 聂志玲, 周小莉. 阿尔茨海默病的中医病因病机探析[J]. 时珍国医国药, 2020, 31(6): 1443-1444. 牟朝清, 马进. 阿尔茨海默病的病因病机研究进展[J]. 山西医药杂志, 2019, 48(4): 435-438. 李星, 张宏, 陶吉明. 阿尔兹海默病本虚标实病机的现代神经生物学探讨[J]. 时珍国医国药, 2023, 34(2): 398-400. 彭杨鹏, 周睿卿, 余建军, 等. 中医药治疗阿尔茨海默病的研究进展[J]. 江西中医药, 2021, 52(9): 74-76. 郭佳越, 汤燚, 杨银, 等. 阿尔茨海默病的病因与发病机制研究进展[J]. 中国医药导报, 2024, 21(1): 39-42. 王亚楠, 任凌, 韩伟, 等. 阿尔茨海默病病理生理机制及其诊断研究进展[J]. 解放军医学杂志, 2025, 50(5): 632-640. 刘雅洁, 林瑶, 赵百孝. 芳香疗法治疗阿尔茨海默病的研究进展[J]. 中华中医药杂志, 2022, 37(7): 3982-3985. 侯锡鸿, 张佩林, 王斯娴, 等. 芳香开窍中药对中枢神经系统疾病的治疗作用研究进展[J]. 药学进展, 2021, 45(5): 372-381. 王纳, 熊磊, 吴忻晨, 等. “芳香开窍” 理论探析[J]. 中国中医基础医学杂志, 2021, 27(9): 1460-1462. 陈佳丽, 张紫钰, 王义豪, 等. 芳香疗法对阿尔茨海默病的影响[J]. 中国疗养医学, 2022, 31(12): 1258-1261. 中国药典[S]. 一部. 2025: 96, 156, 158, 167, 176, 414. 冯鹏, 王明露, 王宇彤, 等. 石菖蒲挥发油化学成分及药理作用研究进展[J]. 中药药理与临床, 2025, 41(6): 100-109. Wang Z F, Zhou J P, Zhang B, et al. Inhibitory effects of β-asarone on lncRNA BACE1-mediated induction of autophagy in a model of Alzheimer’s disease [J]. Behav Brain Res, 2024, 463: 114896. Jung M J, Kim N, Jeon S H, et al. Eugenol relieves the pathological manifestations of Alzheimer’s disease in 5×FAD mice [J]. Phytomedicine, 2023, 118: 154930. Nejabati H R, Roshangar L. Kaempferol as a potential neuroprotector in Alzheimer’s disease [J]. J Food Biochem, 2022, 46(12): e14375. 王浩, 高磊, 张金莲, 等. 石菖蒲中α-细辛醚和β-细辛醚药理作用及机制研究进展[J]. 中国中药杂志, 2025, 50(9): 2305-2316. 邱路雅, 杨刚, 金琼, 等. 石菖蒲根茎化学成分及抗炎活性研究[J]. 中草药, 2022, 53(15): 4617-4624. 李秋实, 李熙东, 田步先, 等. β-细辛醚对APP/PS1小鼠神经炎症的影响及机制研究[J]. 解剖科学进展, 2023, 29(2): 142-145. 方洪, 韩沅沅, 谷丽华, 等. 石菖蒲中乙酰胆碱酯酶抑制剂的筛选[J]. 中成药, 2022, 44(3): 836-841. Xu Z W, Zhou X J, Hong X, et al. Essential oil of Acorus tatarinowii Schott inhibits neuroinflammation by suppressing NLRP3 inflammasome activation in 3×Tg-AD transgenic mice [J]. Phytomedicine, 2023, 112: 154695. Mao J X, Huang S C, Liu S F, et al. A herbal medicine for Alzheimer’s disease and its active constituents promote neural progenitor proliferation [J]. Aging Cell, 2015, 14(5): 784-796. 李旭冉, 陈思邈, 陈伟燕, 等. 远志的化学成分及防治阿尔兹海默症的研究进展[J]. 中国药学杂志, 2022, 57(1): 15-23. 王哲, 崔小川, 周高峰, 等. 远志皂苷改善APP/PS1转基因小鼠认知功能损伤的机制研究[J]. 解放军医学杂志, 2020, 45(4): 398-404. Wang L, Jin G F, Yu H H, et al. Protective effects of tenuifolin isolated from Polygala tenuifolia Willd roots on neuronal apoptosis and learning and memory deficits in mice with Alzheimer’s disease [J]. Food Funct, 2019, 10(11): 7453-7460. Chen Y J, Huang X B, Chen W Q, et al. Neuroprotective effects of tenuigenin on neurobehavior, oxidative stress, and tau hyperphosphorylation induced by intracerebroventricular streptozotocin in rats [J]. Brain Circ, 2018, 4(1): 24. Ren X, Zhang J W, Zhao Y N, et al. Senegenin inhibits Aβ1-42-induced PC12 cells apoptosis and oxidative stress via activation of the PI3K/Akt signaling pathway [J]. Neuropsychiatr Dis Treat, 2022, 18: 513-524. Li J Y, Shan X X, Gao Y, et al. Acori Tatarinowii Rhizoma regulates OCT3/OATP2 and P-gp/MRP1 to “guide medicines upwards” in Kai-Xin-San to treat Alzheimer’s disease [J]. J Ethnopharmacol, 2025, 343: 119484. Dong X Y, Zhou S Y, Nao J F. Kaempferol as a therapeutic agent in Alzheimer’s disease: Evidence from preclinical studies [J]. Ageing Res Rev, 2023, 87: 101910. Liang G C, Gao C X, Zhang L W, et al. Combination of tenuigenin-based Polygala tenuifolia Willd. root extract and forsythoside a improved Alzheimer’s disease [J]. Nat Prod Res, 2025, 39(12): 3570-3574. 周文杰, 李宁, 谢兴文, 等. 天然麝香的化学成分及药理研究进展[J]. 时珍国医国药, 2022, 33(1): 185-188. 杨晓莉, 常艳, 郭东贤, 等. 麝香酮药理学作用研究进展[J]. 中国药业, 2025, 34(5): 后插1-后插5. 韦美岐, 刘桂荣. 麝香酮治疗痴呆的作用机制研究进展[J]. 中国药理学与毒理学杂志, 2023, 37(S1): 65. 弋静, 杨钰莹, 全云云, 等. 麝香及其活性成分的抗炎作用机制与临床应用现状[J]. 中医药导报, 2023, 29(7): 74-80. 秦涛, 邓婷, 徐颖, 等. 基于Wnt/β-catenin信号通路探讨麝香对AD模型大鼠的影响及潜在机制[J]. 中药与临床, 2025, 16(1): 29-35. 姚刚. 麝香酮抗氧化作用的研究进展[J]. 山东化工, 2025, 54(3): 110-112. 谢林江, 秦涛, 宋才友, 等. 麝香对Aβ1-42诱导PC12细胞氧化应激损伤的保护作用研究[J]. 中药药理与临床, 2024, 40(4): 83-89. 齐娜, 段文娟, 李雅婧, 等. 麝香酮药理作用的研究进展[J]. 世界科学技术-中医药现代化, 2020, 22(8): 3042-3047. Liu Y, Bian H J, et al. Muscone ameliorates synaptic dysfunction and cognitive deficits in APP/PS1 mice [J]. J Alzheimer’s Dis, 2020, 76(2): 491-504. Huang P, Sun H, Chen Y A, et al. Muscone enhances synaptic function in vascular dementia through activating BDNF-TrkB-NP2 signaling pathway [J]. Int Immunopharmacol, 2025, 149: 114232. 吴谕锋, 朱泽宇, 陈靖南, 等. 冰片药理作用及冰片酯的研究进展[J]. 药学研究, 2020, 39(4): 217-224. Kulkarni M, Sawant N, Kolapkar A, et al. Borneol: A promising monoterpenoid in enhancing drug delivery across various physiological barriers [J]. AAPS PharmSciTech, 2021, 22(4): 145. Ye T T, Yan X D, Bai H, et al. Borneol regulates meningeal lymphatic valve plasticity to clear Aβ aggregates in the prevention of AD-like symptoms [J]. Phytomedicine, 2024, 130: 155753. Park S H, Lee S, Hong Y K, et al. Suppressive effects of SuHeXiang Wan on amyloid-β42-induced extracellular signal-regulated kinase hyperactivation and glial cell proliferation in a transgenic Drosophila model of Alzheimer’s disease [J]. Biol Pharm Bull, 2013, 36(3): 390-398. 卢秋桃, 洪松彬, 张金礼. GC-MS和LC-MS/MS分析苏合香有效成分及药代动力学研究[J]. 辽宁中医杂志, 2023, 50(11): 182-185. Laws J S, Smid S D. Characterizing Cannabis-prevalent terpenes for neuroprotection reveal a role for α and β-pinenes in mitigating amyloid β-evoked neurotoxicity and aggregation in vitro [J]. Neurotoxicology, 2024, 100: 16-24. Hashemi P, Ahmadi S. Alpha-pinene moderates memory impairment induced by kainic acid via improving the BDNF/TrkB/CREB signaling pathway in rat hippocampus [J]. Front Mol Neurosci, 2023, 16: 1202232. Salehi B, Upadhyay S, Erdogan Orhan I, et al. Therapeutic potential of α- and β-pinene: A miracle gift of nature [J]. Biomolecules, 2019, 9(11): 738. Kumar R, Kumar R, Sharma N, et al. Ameliorative effect of myrcene in mouse model of Alzheimer’s disease [J]. Eur J Pharmacol, 2021, 911: 174529. Khan M A, Alam M M, Ali S M, et al. Camphene mitigates cyclophosphamide-induced oxidative stress, neuroinflammation, and cognitive dysfunction via Nrf2, NF-κB, and astrocytic GFAP modulation in wistar albino rats [J]. J Biochem Mol Toxicol, 2025, 39(9): e70514. 李宗梅, 姚玲玲, 邹宇琛, 等. 安息香药材化学成分、药理作用研究进展及质量标志物预测分析[J]. 世界科学技术-中医药现代化, 2021, 23(11): 4156-4164. Dong Y Q, Stewart T, Bai L D, et al. Coniferaldehyde attenuates Alzheimer’s pathology via activation of Nrf2 and its targets [J]. Theranostics, 2020, 10(1): 179-200. Oliveira C, Bagetta D, Cagide F, et al. Benzoic acid-derived nitrones: A new class of potential acetylcholinesterase inhibitors and neuroprotective agents [J]. Eur J Med Chem, 2019, 174: 116-129. Ghaderi S, Gholipour P, Komaki A, et al. Underlying mechanisms behind the neuroprotective effect of vanillic acid against diabetes-associated cognitive decline: An in vivo study in a rat model [J]. Phytother Res, 2024, 38(3): 1262-1277. 中国医药教育协会. 安宫牛黄丸临床应用专家共识[J]. 中国中西医结合杂志, 2022, 42(8): 933-946. Liu B T, Li Q, Sun K, et al. Angong Niuhuang Wan ameliorates LPS-induced cerebrovascular edema by inhibiting blood-brain barrier leakage and promoting the membrane expression of AQP4[J]. Front Pharmacol, 2024, 15: 1421635. 宋采秋, 刘昱麟, 谢鑫, 等. 经典名方苏合香丸的古代文献与现代临床应用分析[J]. 实用中医内科杂志, 2025, 39(4): 20-25. 陈琳. 开窍醒脑针刺结合菖蒲郁金汤加减治疗老年脑梗死[J]. 世界中医药, 2020, 15(18): 2735-2738. 方亮, 陶文康, 程红艳, 等. 中药引药上行的作用机制及其脑靶向制剂研究进展[J]. 中草药, 2023, 54(10): 3312-3321. 郑资煜, 马进. 还少丹治疗阿尔茨海默病的临床应用与机制研究进展[J]. 实用中医内科杂志, 2025, 39(10): 111-114. 柯敏萱, 李松哲, 孙跃峰, 等. 远志及其复方治疗阿尔茨海默病的研究进展[J]. 天津中医药大学学报, 2024, 43(11): 1021-1031. 李晓青, 赵佳奇, 田雅娟, 等. 远志、石菖蒲及其对药改善记忆的物质基础和作用机制研究进展[J]. 中国实验方剂学杂志, 2019, 25(3): 190-199. 周陆怡, 鲁澄宇. 冰片对丹参脂溶性药效成分促吸收作用研究[J]. 中国药业, 2019, 28(1): 14-18. Gu S Q, Yin W, Xie M Z, et al. Isoquinoline alkaloids in Coptis chinensis to treat Alzheimer’s disease through promoting growth of Bifidobacterium breve inhibiting abnormal autophagy using a novel AI high-content intelligent imaging system [J]. Chin Herb Med, 2026, 18(2): 405-419.
PDF下载
全屏
36
11
关闭全屏
北京市海淀区学院南路86号
010-62199257（仅加盟咨询）
qkjq@cast.org.cn
